Drugs / RQ3013
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05394012 | Dec 2022 → Feb 2023 | COVID-19 | Walvax Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05396573 | Jul → Aug 2022 | COVID-19 | Walvax Biotechnology Co., Ltd. | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05907044 Comparator | May → Jun 2023 | COVID-19 | Affiliated Hospital of Yunnan University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RQ3013 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05394012 ↗ |
| Modality | Messenger RNA (mRNA) | “SARS-CoV-2 mRNA Chimera Vaccine” NCT05396573 ↗ |
| Route | Intramuscular | “The study vaccine is administered IM at upper arm deltoid” NCT05394012 ↗ |